Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felix Y Feng

Showing results (31-40 of 459) with videos related to

Pageof 46
Sort By:
American Journal of Clinical Oncology|December 2, 2014
High-risk Prostate Cancer Treated With Dose-escalated RT: An Analysis of Hormonal Therapy Use and Duration, and Prognostic Implications of PSA Nadir ≤0.2 to Select Men for Short-term Hormonal TherapyChristina H Son, Daniel A Hamstra, Felix Y Feng, et al.
Nature Reviews. Clinical Oncology|June 2, 2016
Translational and clinical implications of the genetic landscape of prostate cancerDaniel E Spratt, Zachary S Zumsteg, Felix Y Feng, et al.
EJNMMI Physics|September 30, 2022
Impact of radiopharmaceutical therapy (<sup>177</sup>Lu, <sup>225</sup>Ac) microdistribution in a cancer-associated fibroblasts modelJonathan Tranel, Stig Palm, Stephen A Graves, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2019
Reply to J.B. Aragon-ChingSeth A Rosenthal, Chen Hu, Oliver Sartor, et al.
Molecular Cell|June 20, 2015
Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor FunctionFelix Y Feng, Johann S de Bono, Mark A Rubin, et al.
Cancer Discovery|February 20, 2020
Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer TherapyJonathan Chou, David A Quigley, Troy M Robinson, et al.
Medical Physics|February 5, 2024
Technical note: Errors introduced when using Dose Voxel Kernels for estimating absorbed dose from radiopharmaceutical therapies involving alpha emittersJonathan Tranel, Stig Palm, Felix Y Feng, et al.
Cancer|October 20, 2011
Interval to biochemical failure as a biomarker for cause-specific and overall survival after dose-escalated external beam radiation therapy for prostate cancerNirav S Kapadia, Karin Olson, Howard M Sandler, et al.
International Journal of Radiation Oncology, Biology, Physics|March 7, 2013
Retrospective evaluation reveals that long-term androgen deprivation therapy improves cause-specific and overall survival in the setting of dose-escalated radiation for high-risk prostate cancerFelix Y Feng, Kevin Blas, Karin Olson, et al.
American Journal of Clinical Oncology|September 26, 2013
Time to Nadir PSA: Of Popes and PSA--The Immortality BiasSkyler B Johnson, William C Jackson, Jure Murgic, et al.
Pageof 46

Showing results (31-40 of 459) with videos related to

Sort By:
Pageof 46
American Journal of Clinical Oncology|December 2, 2014
High-risk Prostate Cancer Treated With Dose-escalated RT: An Analysis of Hormonal Therapy Use and Duration, and Prognostic Implications of PSA Nadir ≤0.2 to Select Men for Short-term Hormonal TherapyChristina H Son, Daniel A Hamstra, Felix Y Feng, et al.
Nature Reviews. Clinical Oncology|June 2, 2016
Translational and clinical implications of the genetic landscape of prostate cancerDaniel E Spratt, Zachary S Zumsteg, Felix Y Feng, et al.
EJNMMI Physics|September 30, 2022
Impact of radiopharmaceutical therapy (<sup>177</sup>Lu, <sup>225</sup>Ac) microdistribution in a cancer-associated fibroblasts modelJonathan Tranel, Stig Palm, Stephen A Graves, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2019
Reply to J.B. Aragon-ChingSeth A Rosenthal, Chen Hu, Oliver Sartor, et al.
Molecular Cell|June 20, 2015
Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor FunctionFelix Y Feng, Johann S de Bono, Mark A Rubin, et al.
Cancer Discovery|February 20, 2020
Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer TherapyJonathan Chou, David A Quigley, Troy M Robinson, et al.
Medical Physics|February 5, 2024
Technical note: Errors introduced when using Dose Voxel Kernels for estimating absorbed dose from radiopharmaceutical therapies involving alpha emittersJonathan Tranel, Stig Palm, Felix Y Feng, et al.
Cancer|October 20, 2011
Interval to biochemical failure as a biomarker for cause-specific and overall survival after dose-escalated external beam radiation therapy for prostate cancerNirav S Kapadia, Karin Olson, Howard M Sandler, et al.
International Journal of Radiation Oncology, Biology, Physics|March 7, 2013
Retrospective evaluation reveals that long-term androgen deprivation therapy improves cause-specific and overall survival in the setting of dose-escalated radiation for high-risk prostate cancerFelix Y Feng, Kevin Blas, Karin Olson, et al.
American Journal of Clinical Oncology|September 26, 2013
Time to Nadir PSA: Of Popes and PSA--The Immortality BiasSkyler B Johnson, William C Jackson, Jure Murgic, et al.
Pageof 46